Plasma histamine and tumour necrosis factor-alpha LEVELS IN Crohn's disease and ulcerative colitis at various stages of disease

Journal of Physiology and Pharmacology

Volumn 66, Issue 4, 2015, Pages 549-556

  Hagel, Alexander F ^a   de Rossi, T ^a   Konturek, P C ^a   Albrecht, H ^a   Walker, S ^a   Hahn, E G ^a   Raithel, M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Crohn's disease; Inflammatory bowel disease; Plasma histamine; Tumor necrosis factor a; Ulcerative colitis

Indexed keywords

HISTAMINE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MRNA EXPRESSION ASSAY; OPHTHALMIC VEIN; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; ULCERATIVE COLITIS; AGED; BLOOD; DISEASE COURSE; INTESTINE FISTULA; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; HISTAMINE; HUMANS; INTESTINAL FISTULA; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84940735468     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Henderson P, van Limbergen JE, Schwarze J, Wilson DC. Function of intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 382-395.
2. Karlinger K, Gyorke T, Mako E, Mester A, Tarjan Z. The epidemiology and the pathogenesis of inklammatory bowel disease. Eur J Radiol 2000; 35: 154-167.
3. Bilski J, Mazur-Bialy AI, Wierdak M, Brzozowski T. The impact of physical activity and nutrition on inflammatory bowel disease: the potential role of cross talk between adipose tissue and skeletal muscle. J Physiol Pharmacol 2013; 64: 143-55.
4. Biesiada G, Czepiel J, Ptak-Belowska A, et al. Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea. J Physiol Pharmacol 2012; 63: 471-481.
5. Gurish M, Castells MC. Mast Cells. UpToDate ®, Version 16.1, 2008, 1-33.
6. Winterkamp S, Weidenhiller M, Otte P, et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 3071-3077
7. Raithel M, Winterkamp S, Weidenhiller M, Muller S, Hahne EG. Combination therapy using fexofenadine, disodium cromoglycate, and a hypoallergenic amino acid-based formula induced remission in a patient with steroid-dependent, chronically active ulcerative colitis. Int J Colorectal Dis 2007; 22: 833-839.
8. Xie H, He SH. Roles of histamine and its receptors in allergic and inflammatory bowel diseases. World J Gastroenterol 2005; 11: 2851-2857.
9. Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 174-179.
10. He SH. Key role of mast cells and major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10: 309-318.
11. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology1998; 115: 182-205.
12. Keyzer Y, Breukelman H, Wolthers B, van den Heuvel M, Kromme N, Berg WC. Urinary excretion of histamine and some of ist metabolites in man: influence of the diet. Agents Actions 1984; 15: 189-194.
13. Raithel M, Nagel A, Zopf Y, et al. Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD). Inflamm Res 2010; 59 (Suppl. 2): S257-S258.
14. TNF-α ELISA, Instruction for Use. Hamburg, IBL Gesellschaft fur Immunchemie und Immunbiologie MBH 2006, pp. 1-33.
15. Histamine ELISA (RE 59221), Hamburg, IBL Gesellschaft fur Immunchemie und Immunbiologie MBH (Version 2) 2006, pp. S1-S7.
16. Fox CC, Lichtenstein LM, Roche JK. Intestinal mast cell responses in idiopathic inflammatory bowel disease. Histamine release from human intestinal mast cells in response to gut epithelial proteins. Dig Dis Sci 1993; 38: 1105-1112.
17. Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990; 99: 119-124.
18. Sanderson IR, Leung KBP, Pearce FL, Walker-Smith JA. Lamina propria mast cells in biopsies from children with Crohn's disease. J Clin Pathol 1986; 39: 279-283.
19. Raithel M, Horauf AM, Matek M, Baenkler HW. Kinetics of histamine released from rectal mucosa. Agents Actions 1989; 28: 164-167.
20. Bachert C. The role of histamine in allergic disease: reappraisal of its inflammatory potential. Allergy 2002; 57: 287-296.
21. Schmidt WU, Sattler J, Hesterberg R, et al. Human intestinal diamine oxidase (DAO) activity in Crohn's disease: A new marker for disease assessment? Agents Actions 1990; 30: 267-270.
22. Petersen J, Raithel M, Schwelberger HG. Analysis of diamine oxidase gene polymorphisms in patients with inflammatory bowel disease. Inflamm Res 2001; 50: (Suppl 2): S68-S69.
23. Bartunkova J, Kolarova I, Sediva A, Holzelova E. Antineutrophil cytoplasmatic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel disease. Clin Immunol 2002; 102: 162-168.
24. Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991; 36: 179-184.
25. Szkudlapski D, Labuzek K, Pokora Z, et al. The emering role of helminths in treatment of the inflammatory bowel disorders. J Physiol Pharmacol 2014; 65: 741-751.
26. Beil WJ, Weller PF, Peppercorn MA, Galli SJ, Dvorak AM.. Ultrastructural immunogold localization of subcellular sites of TNF-a in colonic Crohn's disease. J Leukoc Biol 1995; 58: 284-298.
27. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Locations of tumour necrosis factor-α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-1709.
28. Bouma G, Xia B, Crusius JBA, et al. Distribution of four polymorphism in the tumor necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996; 103: 391-396.
29. Van Deventer SJ. Tumor necrosis factor and Crohn's disease. Gut 1997; 40: 443-448.
30. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-305.
31. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-88.
32. Travis SP, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-42.
33. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4807-4812.
34. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumor necrosis factor a in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-917.
35. Westendorf AM, Templin M, Geffers R, et al. CD4+ T cell mediated intestinal immunity: chronic inflammation versus immune regulation. Gut 2005; 54: 60-69.
36. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12: 3657-3667.
37. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.